---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-074730"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T18:51:39.208699+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q2 2025 net income $63.7M; product sales up 54% YoY; zoliflodacin PDUFA Dec 15

## Summary
- Q2 2025 net income $63.7M ($1.01 basic EPS) vs net loss of $34.7M in Q2 2024.
- GSK royalty revenue $67.3M, flat YoY; IST U.S. net product sales $29.0M (+54% YoY).
- ZEVTERA (ceftobiprole) commercially launched in U.S. July 2025 for three indications.
- Zoliflodacin NDA accepted with Priority Review; PDUFA target date Dec 15, 2025; no AdCom planned.
- Cash & equivalents $397.5M; strategic healthcare asset portfolio valued at $449.3M.

## SEC filing metadata
- accession: 0001104659-25-074730
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465925074730/0001104659-25-074730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465925074730/tm2522376d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-074730
- JSON: https://secwatch.observer/filing/0001104659-25-074730.json
- Plain text: https://secwatch.observer/filing/0001104659-25-074730.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.